Selective GABAA α5 positive allosteric modulators improve cognitive function in aged rats with memory impairment
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
A condition of excess activity in the hippocampal formation is observed in the aging brain and in conditions that confer additional risk during aging for Alzheimer’s disease. Compounds that act as positive allosteric modulators at GABAA α5 receptors might be useful in targeting this condition because GABAA α5 receptors mediate tonic inhibition of principal neurons in the affected network. While agents to improve cognitive function in the past focused on inverse agonists, which are negative allosteric modulators at GABAA α5 receptors, research supporting that approach used only young animals and predated current evidence for excessive hippocampal activity in age-related conditions of cognitive impairment. Here, we used two compounds, Compound 44 [6,6-dimethyl-3-(3-hydroxypropyl)thio-1-(thiazol-2-yl)-6,7-dihydro-2-benzothiophen-4(5H)-one] and Compound 6 [methyl 3,5-diphenylpyridazine-4-carboxylate], with functional activity as potentiators of γ-aminobutyric acid at GABAA α5 receptors, to test their ability to improve hippocampal-dependent memory in aged rats with identified cognitive impairment. Improvement was obtained in aged rats across protocols differing in motivational and performance demands and across varying retention intervals. Significant memory improvement occurred after either intracereboventricular infusion with Compound 44 (100 μg) in a water maze task or systemic administration with Compound 6 (3 mg/kg) in a radial arm maze task. Furthermore, systemic administration improved behavioral performance at dosing shown to provide drug exposure in the brain and in vivo receptor occupancy in the hippocampus. These data suggest a novel approach to improve neural network function in clinical conditions of excess hippocampal activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palop, J. J., Chin, J., Roberson, E. D., Wang, J., Thwin, M. T., Bien-Ly, N., Yoo, J., Ho, K. O., Yu, G.-Q., Kreitzer, A., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.07.025 · Cited by 1,653 · cited 2×
“Moreover, aberrant excitability is found in the hippocampal system in transgenic mice overexpressing amyloid precursor protein (Palop et al., 2007) and in mouse models of ApoE4 (Andrews-Zwilling et al., 2010), a genotype that confers greatly elevated risk for sporadic AD.”
BackgroundPatterns of Brain Activation in People at Risk for Alzheimer's Disease
Bookheimer, S. Y., Strojwas, M. H., Cohen, M. S., Saunders, A. M., Pericak-Vance, M. A., Mazziotta, J. C., & Small, G. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008173430701 · Cited by 1,328 · cited 2×
“Consistent with evidence in such animal models, data from functional magnetic resonance imaging (fMRI) has revealed increased activation in the hippocampal system in elderly humans with memory impairment, including those meeting criteria for amnestic mild cognitive impairment (aMCI) and in carriers of an ApoE4 allele…”
BackgroundFritschy, J., & Mohler, H. (1995) · Journal of Comparative Neurology · doi:10.1002/cne.903590111 · Cited by 1,244
Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD
Dickerson, B. C., Salat, D. H., Greve, D. N., Chua, E. F., Rand-Giovannetti, E., Rentz, D. M., Bertram, L., Mullin, K., Tanzi, R. E., Blacker, D., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000171450.97464.49 · Cited by 910 · cited 2×
“Consistent with evidence in such animal models, data from functional magnetic resonance imaging (fMRI) has revealed increased activation in the hippocampal system in elderly humans with memory impairment, including those meeting criteria for amnestic mild cognitive impairment (aMCI) and in carriers of an ApoE4 allele…”
BackgroundNeuronal activity regulates the regional vulnerability to amyloid-β deposition
Bero, A. W., Yan, P., Roh, J. H., Cirrito, J. R., Stewart, F. R., Raichle, M. E., Lee, J.-M., & Holtzman, D. M. (2011) · Nature Neuroscience · doi:10.1038/nn.2801 · Cited by 880
Busche, M. A., Chen, X., Henning, H. A., Reichwald, J., Staufenbiel, M., Sakmann, B., & Konnerth, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206171109 · Cited by 715
Yassa, M. A., Lacy, J. W., Stark, S. M., Albert, M. S., Gallagher, M., & Stark, C. E. L. (2011) · Hippocampus · doi:10.1002/hipo.20808 · Cited by 595
Self-citationYassa, M. A., Stark, S. M., Bakker, A., Albert, M. S., Gallagher, M., & Stark, C. E. L. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.03.040 · Cited by 523
Self-citationGABA-based therapeutic approaches: GABAA receptor subtype functions
RUDOLPH, U., & MOHLER, H. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.10.003 · Cited by 499 · cited 1×
“…with selectivity for subtypes of GABAA receptors have been under development for a number of psychiatric and neurological indications, attention surrounding α5 selective agents has largely focused on drugs that are negative modulators of GABA (for review, see Rudolph and Möhler, 2006; Atack 2011).”
BackgroundAndrews-Zwilling, Y., Bien-Ly, N., Xu, Q., Li, G., Bernardo, A., Yoon, S. Y., Zwilling, D., Yan, T. X., Chen, L., & Huang, Y. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4040-10.2010 · Cited by 326
Cited by
Bakker, A., Albert, M. S., Krauss, G., Speck, C. L., & Gallagher, M. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.02.009 · Cited by 286
Self-citationLocci, A., & Pinna, G. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13843 · Cited by 132
Cavanagh, C., Tse, Y. C., Nguyen, H.-B., Krantic, S., Breitner, J. C. S., Quirion, R., & Wong, T. P. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.07.009 · Cited by 79
Piantadosi, S. C., French, B. J., Poe, M. M., Timić, T., Marković, B. D., Pabba, M., Seney, M. L., Oh, H., Orser, B. A., Savić, M. M., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00446 · Cited by 67
Metadata
- Authors
- Koh, M. T., Rosenzweig-Lipson, S., & Gallagher, M.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 64
- Pages
- 145-152
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2011900900
- Cited by
- 118
- References
- 11
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective GABAA α5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. https://app.cochat.ai/papers/10.1016/j.neuropharm.2012.06.023
- The paper
- Koh, M. T., Rosenzweig-Lipson, S., & Gallagher, M. (2013). Selective GABAA α5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2012.06.023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.